ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

RGT Argent Biopharma Limited

21.00
-1.00 (-4.55%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Argent Biopharma Limited LSE:RGT London Ordinary Share AU0000326647 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -4.55% 21.00 20.00 22.00 21.00 21.00 21.00 461 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

ReGen Therapeutics Plc Purchase of Filtration Unit

29/07/2010 7:01am

UK Regulatory



 
TIDMRGT 
 
ReGen Purchases Filtration Unit in anticipation of Increased Demand for its 
Nutraceutical Product - Colostrinin(TM) 
 
29 July 2010 
 
ReGen Therapeutics Plc ('ReGen' or the 'Company') <AIM:RGT> announces that it 
has recently ordered a custom made filtration unit for use in the production of 
its nutraceutical product Colostrinin(TM). 
 
Previously ReGen has hired this equipment, which is used for a key stage in its 
proprietary Colostrinin(TM) production process, performed by its contract 
manufacturer Sterling Technology Inc., in Brookings, South Dakota, USA.  Some of 
the monies raised during the summer were to fund this important and vital 
addition to the Company's assets. 
 
When ReGen had only one major customer to service, hiring such equipment was the 
prudent thing to do. With the recent signing of new licensees in Turkey and 
India and anticipated developments in other markets ReGen believes that now is 
the time to invest in dedicated equipment so that we are best placed to service 
our current and future customers. 
 
Colostrinin(TM) is a nutritional supplement to 'support healthy brain ageing and 
cognition in humans'. It is marketed as a nutritional supplement in the US, 
Canada, Australia and Poland under the brand name CogniSure(TM) *, in Cyprus 
under the brand name Cognase(TM) ** and in the UK under the brand name 
MemoryAid***. Colostrinin(TM) is now in the process of being launched as 
Dyna(TM) in the Republic of Turkey by Eczacibasi and as Cognate (TM) by USV 
Limited in India. 
 
*CogniSure(TM) for use as a human nutraceutical is licensed in North America and 
Australasia to Metagenics Inc. of  San Clemente, California 
(http://www.metagenics.com/). 
 
CogniSure(TM) is distributed in Poland by Tagerr Polska,  an affiliate of Tagerr 
a professional services and trading company established in Köln, Germany. 
(http://www.cognisure.eu/) 
 
** Cognase(TM) is distributed in the Republic of Cyprus by Golgi Pharmaceuticals 
Ltd (http://www.healthybrainaging.com/). 
 
*** MemoryAid is distributed in the UK by PRG Nutraceuticals Ltd 
(http://www.memoryaid.com/) 
 
For further information: 
 
Percy Lomax 
ReGen Therapeutics Plc 
Tel No 020 7153 4920 
 
Roland Cornish/Felicity Geidt 
Beaumont Cornish Limited 
Tel No 020 7628 3396 
 
Nick Bealer/David Scott 
Alexander David 
Tel No 020 7448 9820 
 
 
 
[HUG#1434598] 
 
 
 
 
 
 
 
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: ReGen Therapeutics Plc via Thomson Reuters ONE 
 

1 Year Argent Biopharma Chart

1 Year Argent Biopharma Chart

1 Month Argent Biopharma Chart

1 Month Argent Biopharma Chart